Establishment of a Registry of Patients With Parathyroid Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
About this trial
Establishment of a registry with which to census all patients under the care of the O.U. Endocrinology for parathyroid pathology in order to longitudinally evaluate biochemical, clinical, radiological, medico-nuclear and histological data in future studies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Diagnosis of hyperparathyroidism or hypoparathyroidism based on biochemical parameters (calcemia, parathormone, phosphormia, creatinine, albumin, vitamin D25OH)
Obtaining informed consent
Disqualifiers
none
Trial population
Inclusion in the registry will be offered consecutively to any patient with parathyroid pathology (hyperparathyroidism or hypoparathyroidism) diagnosed and evaluated at the Endocrinology Operating Unit through at least two endocrinology visits. The registry will include patients seen from 1/1/2000 for a duration of 30 years. Follow-up duration for each patient is expected to be 10 years, with enrollment until 12/31/2029, and registry update deadline on 12/31/2039.
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Longitudinal Biochemical Monitoring in Patients with Parathyroid Pathology
This outcome measure will specifically assess and report biochemical parameters in patients with parathyroid pathology under the care of the O.U. Endocrinology. Key biochemical markers to be measured include: Serum calcium levels (mmol/L) Serum phosphorus levels (mmol/L) Parathyroid hormone (PTH) levels (pg/mL) Vitamin D levels (ng/mL) Each parameter will be measured at baseline and at predefined intervals throughout the study. The collected data will be summarized as means ± standard deviations for continuous variables or as proportions for categorical data, where appropriate.
Time frame
through study completion, an average of 15 years2
Clinical Outcomes in Parathyroid Pathology: Symptom Severity, Biochemical Parameters, and Comorbidities
This outcome measure includes the assessment of multiple clinical parameters related to parathyroid pathology. These include: Symptom Severity: Assessed using a standardized symptom severity scale, reported as a score. Biochemical Parameters: Measurement of serum calcium levels (mg/dL) and parathyroid hormone (PTH) levels (pg/mL), summarized as means ± standard deviation. Comorbidities: Documented as binary variables (present/absent) and reported as prevalence percentages.
Time frame
through study completion, an average of 15 years3
Radiological Assessments in Parathyroid Pathology: Imaging Findings and Anatomical Evaluation
This outcome measure involves the collection and evaluation of radiological data to assess the anatomical and functional status of the parathyroid glands and related structures. Specific assessments include: Ultrasound Findings: Measurement of gland size (in centimeters) and structural abnormalities. CT and MRI Results: Detection of anatomical changes or lesions, reported as present/absent and described qualitatively. Bone Scans: Evaluation of bone metabolism abnormalities, summarized as binary outcomes (normal/abnormal). Each imaging modality will be analyzed and reported independently, with results summarized based on specific Units of Measure, such as size (cm) or qualitative descriptors.
Time frame
through study completion, an average of 15 years4
Medico-Nuclear Outcomes: Parathyroid Imaging and Functional Assessment
This outcome measure focuses on data obtained from nuclear medicine imaging to evaluate parathyroid gland function. Specific assessments include: Sestamibi Scan Results: Reported as qualitative findings (e.g., positive/negative for abnormal uptake) and quantified when applicable (e.g., uptake percentage). Additional Imaging Modalities: Data from parathyroid-specific imaging (e.g., PET/CT or ultrasound) will include quantitative parameters such as gland size (cm³) and uptake intensity scores. Each imaging modality will be analyzed and reported separately using appropriate Units of Measure. Aggregation methods will be clarified if data from multiple imaging types are combined to inform a single outcome metric.
Time frame
through study completion, an average of 15 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov